MARKET

IBIO

IBIO

Ibio
NASDAQ
1.440
-0.010
-0.69%
Opening 11:02 07/14 EDT
OPEN
1.470
PREV CLOSE
1.450
HIGH
1.470
LOW
1.425
VOLUME
191.34K
TURNOVER
--
52 WEEK HIGH
3.820
52 WEEK LOW
0.5562
MARKET CAP
71.54M
P/E (TTM)
-1.7337
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IBIO last week (0706-0710)?
Weekly Report · 1d ago
Weekly Report: what happened at IBIO last week (0629-0703)?
Weekly Report · 07/06 09:56
Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal
NASDAQ · 07/02 14:09
iBio Is Maintained at Buy by Chardan Capital
Dow Jones · 07/02 09:45
iBio Price Target Maintained With a $5.00/Share by Chardan Capital
Dow Jones · 07/02 09:45
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO)
TipRanks · 07/02 06:40
Buy Rating Reiterated on iBio as IBIO-610 Data Underscore Differentiated Efficacy; $5 Price Target Maintained
TipRanks · 07/01 19:15
IBio's IBIO-610 Achieves Near-Complete Activin E Inhibition In Obese Primate Study
NASDAQ · 07/01 12:38
More
About IBIO
iBio, Inc. is a biotech company leveraging artificial intelligence and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. It has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.

Webull offers Ibio Inc stock information, including NASDAQ: IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.